Comparison of sugammadex vs neostigmine for reversing the effect of muscle relaxants in thoracic surgery

Comparison of efficacy of sugammadex versus neostigmine for reversal of neuromuscular blockade in patients undergoing non-cardiac thoracic surgery:a prospective, randomised, double-blind study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/073124

Enrollment

Registered

2024-08-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J852- Abscess of lung without pneumonia Health Condition 2: B671- Echinococcus granulosus infectionof lung Health Condition 3: C341- Malignant neoplasm of upper lobe,bronchus or lung Health Condition 4: J65- Pneumoconiosis associated with tuberculosis Health Condition 5: J860- Pyothorax with fistula

Interventions

Intervention1: sugammadex vs neostigmine: Comparison of sugammadex vs neostigmine: Patients will receive inj. Neostigmine 0.05mg/kg of actual body weight (maximum dose 5mg)accompanied by 0.008mg/kg of

Eligibility

Inclusion criteria

Inclusion criteria: Subject willing to participate American society of anaesthesiologist (ASA)physical status classification score I to III Patients having stable vital signs including heart rate, blood pressure,body temperature and respiration Patients receiving vecuronium for neuromuscular blockade

Exclusion criteria

Exclusion criteria: Patient refusal. ASA more than III, pregnancy, lactation, BMI more than30Kg per m2 Patients with inadequate left ventricular ejection fraction (Ejection Fraction less than 45 percent),valvular or ischaemic heart disease,uncontrolled hypertension,heart blocks,arrhythmia,cardiac failure,uncontrolled diabetes mellitus Abnormal hepatic, renal function test. Coexisting medical comorbidities like hepatic, renal, endocrine, haematological, autoimmune, psychiatric, neurological diseases. Allergy to study drugs. Lung cancer with metastasis. Patients receiving atracurium and cisatracurium. Thoracic trauma

Design outcomes

Primary

Measure	Time frame
compare time taken to achieve Train of four ratio (TOFr) =0.9 after the administration of reversal agent.Timepoint: upto 30 mins after administration of reversal agent.	—

Secondary

Measure	Time frame
To compare other recovery criteria such asTime to extubation, time to achieve sustained head lift for more than 5 sec after administration of reversal agent.Timepoint: upto 30 mins after administration of reversal agent.;To compare postoperative adverse respiratory event related to PORC. To compare drug adverse effects related to reversal agent. To compare patient outcome -all cause mortality . Timepoint: upto 24hr after administration of reversal agent.	—

Measure

Time frame

To compare other recovery criteria such asTime to extubation, time to achieve sustained head lift for more than 5 sec after administration of reversal agent.Timepoint: upto 30 mins after administration of reversal agent.;To compare postoperative adverse respiratory event related to PORC. To compare drug adverse effects related to reversal agent. To compare patient outcome -all cause mortality . Timepoint: upto 24hr after administration of reversal agent.

—

Countries

India

Contacts

Public ContactDr Manish Rao

R.N.T Medical College

uditanaithani@gmail.com9829414752

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026